|
A Study on the Use of Evidence Based Therapy (EBT) in the Treatment of Type 2 Diabetes Mellitus in a Private Healthcare Facility in Malaysia
|
|
| Author:
|
, BAMA VV MENON, YAMAN WALID KASSAB, HANISH SINGH JEYASINGH CHELLAMMAL, ANANDARAJAGOPAL KALUSALINGAM, ABDULLAH KHAN
|
| Abstract:
|
The purpose of this study was to access the prescribing pattern and determine the sociodemographic and clinical predictors of prescribing of antidiabetics in a private hospital. This study also aimed to evaluate prescription adherence to the Clinical Practice Guideline (CPG) for the Management of Type 2 Diabetes Mellitus (T2DM). This cross-sectional study included a random sample of 115 patients selected from the patients referred to the diabetic nurse educator in a private hospital. A retrospective data collection method was adopted with a specially devised data collection sheet, which consists of four parts. Poor glycaemic control was observed in 66.1% of patients, with a mean glycosylated hemoglobin A1c (HbA1c) of 9.3 ± 2.2. A Significant correlation was found between HbA1c and the number of antidiabetics prescribed (p =0.047). Metformin was the most prescribed antidiabetic, followed by Gliclazide and Sitagliptin. Insulin usage was limited to 15.7% only. The most commonly combined dual therapy was Metformin with Gliclazide, followed by Metformin with Sitagliptin. Significant negative predictors of the prescription of Metformin were patients with renal dysfunction and taking beta-blockers for the treatment of comorbidities. The involvement of coronary artery disease enhanced the probability of prescribing Sitagliptin by 47 (95 per cent CI 1.1-19.1). Overall, in only about 48 per cent of patients, adherence to guidelines could be seen. In conclusion, this research revealed that adherence to Malaysian CPG was found to be low for T2DM management. In this private hospital, Dipeptidyl Peptidase 4 (DPP4) inhibitors were commonly used, although insulin usage was minimal.
|
| Keyword:
|
Prescribing pattern, Evidence based therapy, Type 2 Diabetes Mellitus, glycaemic control
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2021.13.03.099
|
| Download:
|
Request For Article
|
|
|